Moxetumomab pasudotox - MedImmune

Drug Profile

Moxetumomab pasudotox - MedImmune

Alternative Names: CAT-8015; GCR-8015; HA22; LUMOXITI

Latest Information Update: 17 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer M. D. Anderson Cancer Center; MedImmune; National Cancer Institute (USA)
  • Class Antineoplastics; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Peptide elongation factor 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hairy cell leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hairy cell leukaemia
  • Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 17 Sep 2018 Astra Zeneca announces intention to submit MAA to European Medicines Agency (EMA) for Hairy cell leukaemia in 2018
  • 14 Sep 2018 Updated safety and efficacy data from a phase III trial in Hairy cell leukaemia released by MedImmune
  • 13 Sep 2018 Registered for Hairy cell leukaemia (Second-line therapy or greater) in USA (IV) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top